| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/SCHBUL/SBX199 |
| P8608 | Fatcat ID | release_eve3ykp365e7xlmuqldobzluwm |
| P932 | PMC publication ID | 6293217 |
| P698 | PubMed publication ID | 29385549 |
| P50 | author | Felipe V. Gomes | Q47705373 |
| P2093 | author name string | Anthony A Grace | |
| P2860 | cites work | The dopamine hypothesis of schizophrenia: version III--the final common pathway | Q22242827 |
| Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. | Q24681363 | ||
| Translating the MAM model of psychosis to humans | Q26860217 | ||
| Cortical inhibitory neurons and schizophrenia | Q29547683 | ||
| Abnormal stress responsivity in a rodent developmental disruption model of schizophrenia | Q30429962 | ||
| A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia | Q30465716 | ||
| Synaptic and nonsynaptic localization of GABAA receptors containing the alpha5 subunit in the rat brain | Q30826932 | ||
| Mesoprefrontal cortical dopaminergic activity and prefrontal hypofunction in schizophrenia | Q33198729 | ||
| Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies | Q33833648 | ||
| Schizophrenia: genes and environment | Q33842577 | ||
| Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia | Q33889886 | ||
| To model a psychiatric disorder in animals: schizophrenia as a reality test | Q33913794 | ||
| Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia | Q33963430 | ||
| Effects of ketamine in normal and schizophrenic volunteers | Q34091266 | ||
| Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research | Q34147040 | ||
| Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model | Q34167594 | ||
| Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo | Q34371074 | ||
| Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient | Q34463410 | ||
| Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity | Q34466181 | ||
| The "delayed onset" of antipsychotic action--an idea whose time has come and gone. | Q34480502 | ||
| A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia | Q35158189 | ||
| Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia | Q35197029 | ||
| Divergent activation of ventromedial and ventrolateral dopamine systems in animal models of amphetamine sensitization and schizophrenia | Q35230683 | ||
| The stress cascade and schizophrenia: etiology and onset | Q35677879 | ||
| Role of the ventral subiculum in stress integration. | Q36550474 | ||
| Compensations after lesions of central dopaminergic neurons: some clinical and basic implications | Q36586049 | ||
| Regulation of firing of dopaminergic neurons and control of goal-directed behaviors | Q36776758 | ||
| Perineuronal nets protect fast-spiking interneurons against oxidative stress | Q36895825 | ||
| Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study | Q36928703 | ||
| The nature of dopamine dysfunction in schizophrenia and what this means for treatment | Q37062793 | ||
| Entrainment of neocortical neurons and gamma oscillations by the hippocampal theta rhythm | Q37092520 | ||
| PRENATAL INFECTION, MATERNAL IMMUNE ACTIVATION, AND RISK FOR SCHIZOPHRENIA. | Q37097440 | ||
| Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia | Q37103318 | ||
| A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia | Q37369353 | ||
| Loss of Parvalbumin in the Hippocampus of MAM Schizophrenia Model Rats Is Attenuated by Peripubertal Diazepam | Q37472623 | ||
| Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia | Q37598278 | ||
| Amygdala-ventral pallidum pathway decreases dopamine activity after chronic mild stress in rats | Q37671722 | ||
| Hippocampal pathology in schizophrenia. | Q37839953 | ||
| Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia | Q37881426 | ||
| Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model | Q38846609 | ||
| Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression | Q38852249 | ||
| Phosphodiesterase 10 inhibitors in clinical development for CNS disorders | Q39029199 | ||
| Prefrontal Cortex Dysfunction Increases Susceptibility to Schizophrenia-Like Changes Induced by Adolescent Stress Exposure | Q39076734 | ||
| Involvement of Infralimbic Prefrontal Cortex but not Lateral Habenula in Dopamine Attenuation After Chronic Mild Stress. | Q39215368 | ||
| The environment and schizophrenia | Q39958490 | ||
| Which GABAA-receptor subtypes really occur in the brain? | Q41003268 | ||
| Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs | Q41326381 | ||
| Amygdala Hyperactivity in MAM Model of Schizophrenia is Normalized by Peripubertal Diazepam Administration | Q41725359 | ||
| Dopamine System Dysregulation and the Pathophysiology of Schizophrenia: Insights From the Methylazoxymethanol Acetate Model | Q42781646 | ||
| Increased synaptic dopamine function in associative regions of the striatum in schizophrenia | Q43145582 | ||
| Redox dysregulation affects the ventral but not dorsal hippocampus: impairment of parvalbumin neurons, gamma oscillations, and related behaviors. | Q43158698 | ||
| Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission | Q44536213 | ||
| Long-term effects of amygdala GABA receptor blockade on specific subpopulations of hippocampal interneurons | Q45070193 | ||
| Elevated striatal dopamine function linked to prodromal signs of schizophrenia | Q46174418 | ||
| Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern | Q46348068 | ||
| The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation | Q46829207 | ||
| Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. | Q46945434 | ||
| Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, mul | Q47954198 | ||
| The prefrontal cortex regulates lateral amygdala neuronal plasticity and responses to previously conditioned stimuli. | Q48125179 | ||
| The organization of midbrain projections to the striatum in the primate: sensorimotor-related striatum versus ventral striatum | Q48153250 | ||
| Neurotoxic or electrolytic lesions of the ventral subiculum produce deficits in the acquisition and expression of Pavlovian fear conditioning in rats | Q48193249 | ||
| Dopamine synthesis capacity in patients with treatment-resistant schizophrenia | Q48350915 | ||
| Neocortical modulation of the amygdala response to fearful stimuli | Q48361349 | ||
| Amphetamine psychosis: behavioral and biochemical aspects | Q48597445 | ||
| Provocation of Schizophrenic Symptoms by Intravenous Administration of Methylphenidate | Q48685184 | ||
| Differential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine Neurons | Q48738943 | ||
| Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons | Q48772771 | ||
| Schizophrenia | Q56959104 | ||
| Organization of the ascending striatal afferents in monkeys | Q71497402 | ||
| Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia | Q74630497 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 148-157 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Schizophrenia Bulletin | Q4049133 |
| P1476 | title | The Circuitry of Dopamine System Regulation and its Disruption in Schizophrenia: Insights Into Treatment and Prevention | |
| P478 | volume | 45 |
| Q99402872 | A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis |
| Q88502234 | Altered brain cannabinoid 1 receptor mRNA expression across postnatal development in the MAM model of schizophrenia |
| Q52639825 | Disrupted network cross talk, hippocampal dysfunction and hallucinations in schizophrenia. |
| Q90748306 | Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study |
| Q58769221 | Medial septum activation produces opposite effects on dopamine neuron activity in the ventral tegmental area and substantia nigra in MAM vs. normal rats |
| Q60625022 | Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis |
| Q60951051 | The Role of Frontostriatal Systems in Instructed Reinforcement Learning: Evidence From Genetic and Experimentally-Induced Variation |
| Q90728397 | The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia |
| Q93133919 | The pathophysiological impact of stress on the dopamine system is dependent on the state of the critical period of vulnerability |
| Q58618125 | Towards a Unifying Cognitive, Neurophysiological, and Computational Neuroscience Account of Schizophrenia |
| Q52562792 | α7 Nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia. |
Search more.